Abcam Plc has entered into a definitive license agreement with F. Hoffmann-La Roche Ltd. to obtain the exclusive rights to the product portfolio of Spring Bioscience Corporation (Spring) in the research use only (RUO) field of use, comprising a total of approximately 760 unique products (the Spring Portfolio). The core portfolio consists of 243 recombinant rabbit monoclonal antibodies, branded Spring Proprietary Clones (SP Clones), which have been optimised for immunohistochemistry (IHC). In addition to the SP Clones, the agreement covers approximately 500 additional products, predominantly other monoclonal and polyclonal antibodies. All products will be sold under the Abcam brand, inclusive of SP branding, and are expected to be available through Abcam.com from 21 February 2018. Under the terms of the agreement, Abcam has also been granted exclusive RUO rights for all future products developed by Spring that Roche requests to be ommercialised in the RUO field of use for an initial period of 10 years and then extendable on mutually agreeable terms. The transaction enables Abcam to provide customers with the quality recombinant antibodies for their research.